;
Skip to main content
Home > SciBX > Translational Notes

Chronological Index of : Translational Notes

 Current Issue
  • Expanding into new (bromo)domains

    The Neomed Institute has begun development of its first cancer therapeutic, a BRD4 inhibitor from Epigenetix that the not-for-profit organization thinks could have a selectivity advantage over competing molecules.

    Published on 4/17/2014
  • Translational tidbits

    AstraZeneca had a busy March, announcing five new public-private partnerships and launching its Open Innovation website to list additional partnership opportunities.

    Published on 4/17/2014
  • Table 1: Selected public-private partnerships for March 2014

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for March 2014. AstraZeneca plc (LSE:AZN; NYSE:AZN) had a busy March. The pharma is embarking on a broad, five-year screening …

    Published on 4/17/2014
  • Bridging the German gap

    Evotec has purchased Bionamics to gain access to a collection of autoimmune assets sourced from German universities. The move is the latest in a series of steps taken by Evotec to complement its fee-for-service …

    Published on 4/3/2014
  • Explaining the exceptions

    The identification of activating mutations in mTOR that explain an exceptional response in a patient with bladder cancer is the latest example of mechanistic insights that can be gleaned from analyzing exceptional …

    Published on 3/27/2014
  • Teaching translation

    Although public-private partnerships and tech transfer offices provide paths for commercializing academic discoveries, many ideas languish because researchers lack the experience to navigate translation. Several …

    Published on 3/27/2014
  • Easy Access IP: ahead of the game or easy way out?

    As university technology transfer offices grapple with how best to commercialize their discoveries, some are experimenting with different operating models that vary in the number and type of inventions they pursue for …

    Published on 3/20/2014
  • Translational tidbits

    At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH's Accelerating Medicines Partnership.

    Published on 3/20/2014
  • Table 1: Selected public-private partnerships for February 2014

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for February 2014. Over $440 million in new funding commitments and in-kind contributions was earmarked for public-private …

    Published on 3/20/2014
  • Repairing reproducibility

    Although the NIH is taking steps to improve the reproducibility of preclinical data, many researchers are not waiting for guidelines and instead are angling to elevate standards at their own institutions.

    Published on 3/13/2014
  • Herding catalysts at UCSF

    AstraZeneca has made its first beachhead in the Bay Area. The pharma's MedImmune unit has piggybacked onto an NIH-sponsored initiative to support translational research at UCSF.

    Published on 2/27/2014
  • BAND-aid for PD and AD

    Evidence for overlaps between PD and AD have led three foundations to launch the BAND grant program to fund cross-disease research. The studies will use outputs from both the Parkinson's Progression Markers Initiative …

    Published on 2/20/2014
  • A gift for research

    An anonymous $275 million gift propels the Sanford-Burnham Medical Research Institute more than halfway to its funding goal for a newly announced 10-year drug development plan that involves speeding the development of …

    Published on 2/13/2014
  • NCATS two years later

    Comments from Christopher Austin, director of the National Center for Advancing Translational Sciences, on how the center is delivering on its promise to overcome roadblocks and accelerate the translational process.

    Published on 1/30/2014
  • Translational tidbits

    Amgen is teaming up with researchers at MGH and the Broad Institute to find new targets in inflammatory bowel disease. Two European drug discovery centers and an Italian CRO have partnered to launch a drug screening …

    Published on 1/30/2014
  • Table 1: Selected public-private partnerships for December 2013

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for December 2013. Companies Institutions Business area Disclosed value Purpose Table 1. Selected public-private …

    Published on 1/30/2014
  • A new standard in reproducibility

    To address the problem of irreproducibility of preclinical studies, the Global Biological Standards Institute will form task forces to develop much-needed material and procedural standards in key research areas.

    Published on 1/23/2014
  • Tables turning for TTOs

    A Brookings Institution report has helped quantify inefficiencies and expenses associated with licensing university patents. The report advocates an emphasis on company creation instead of IP protection, although …

    Published on 1/23/2014
  • Table 1: Johnson & Johnson Innovation's deal pipeline

    Translational Notes: Biotech kibbutz Table 1. Johnson & Johnson Innovation's deal pipeline. Source: Johnson & Johnson press release J&J site Partner Disease area Project Boston Innovation Center The University …

    Published on 1/16/2014
  • Biotech kibbutz

    Johnson & Johnson and Takeda have partnered with the Israeli government and OrbiMed Israel Partners to build FutuRx, a collectively owned biotech incubator. The incubator is part of a global portfolio of partnerships …

    Published on 1/16/2014
  • Translational tidbits

    GSK opens its doors to an academic consortium and sets up an R&D outpost in San Diego. Also, a roundup of public-private partnerships led by a trio of new consortia funded by the EU's FP7.

    Published on 12/19/2013
  • Table 1: Selected public-private partnerships for November 2013

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for November 2013. Public-private partnership activity was almost nonexistent in the U.S. in November, thanks in part to the …

    Published on 12/19/2013
  • Box 1: Rules of engagement

    Translational Notes: A conversation with Chris Lipinski Box 1. Rules of engagement. Chris Lipinski and colleagues at Pfizer Inc. defined the 'rule of five' after analyzing the physicochemical properties of over 2,…

    Published on 12/5/2013
  • A conversation with Chris Lipinski

    Although the 'rule of five' has altered medicinal chemistry for oral small molecule drugs, Chris Lipinski believes that predicting the behavior of newer biologics might not be far off, and optimization of RNA or protein…

    Published on 12/5/2013
  • Translational tidbits

    The Cancer Prevention & Research Institute of Texas is back in the grant-making business, GlaxoSmithKline picks academic projects for drug screening collaborations, and a roundup of public-private partnerships.

    Published on 11/7/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993